MA40761A - Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr - Google Patents

Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr

Info

Publication number
MA40761A
MA40761A MA040761A MA40761A MA40761A MA 40761 A MA40761 A MA 40761A MA 040761 A MA040761 A MA 040761A MA 40761 A MA40761 A MA 40761A MA 40761 A MA40761 A MA 40761A
Authority
MA
Morocco
Prior art keywords
fgfr
cancer
sensitive
treatment
mutant gene
Prior art date
Application number
MA040761A
Other languages
English (en)
Other versions
MA40761B1 (fr
Inventor
Jayaprakash Karkera
Suso Jesus Platero
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54337343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40761A publication Critical patent/MA40761A/fr
Publication of MA40761B1 publication Critical patent/MA40761B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA40761A 2014-09-26 2015-09-18 Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr MA40761B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056159P 2014-09-26 2014-09-26
PCT/US2015/050996 WO2016048833A2 (fr) 2014-09-26 2015-09-18 Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr

Publications (2)

Publication Number Publication Date
MA40761A true MA40761A (fr) 2017-08-01
MA40761B1 MA40761B1 (fr) 2022-04-29

Family

ID=54337343

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40761A MA40761B1 (fr) 2014-09-26 2015-09-18 Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr

Country Status (38)

Country Link
US (3) US20160090633A1 (fr)
EP (2) EP4063516A1 (fr)
JP (4) JP6766037B2 (fr)
KR (3) KR102839867B1 (fr)
CN (1) CN107002141B (fr)
AR (1) AR102345A1 (fr)
AU (3) AU2015321626B2 (fr)
CA (1) CA2962075C (fr)
CO (1) CO2017003528A2 (fr)
CR (1) CR20170104A (fr)
CY (1) CY1125190T1 (fr)
DK (1) DK3198033T3 (fr)
EA (1) EA037920B1 (fr)
EC (1) ECSP17025787A (fr)
ES (1) ES2912567T3 (fr)
GT (1) GT201700059A (fr)
HR (1) HRP20220496T1 (fr)
HU (1) HUE058219T2 (fr)
IL (3) IL324511A (fr)
JO (1) JO3681B1 (fr)
LT (1) LT3198033T (fr)
MA (1) MA40761B1 (fr)
MX (2) MX392774B (fr)
MY (1) MY194567A (fr)
NI (1) NI201700035A (fr)
PH (1) PH12017500556A1 (fr)
PL (1) PL3198033T3 (fr)
PT (1) PT3198033T (fr)
RS (1) RS63178B1 (fr)
SG (1) SG11201702381QA (fr)
SI (1) SI3198033T1 (fr)
SM (1) SMT202200177T1 (fr)
SV (1) SV2017005415A (fr)
TW (1) TWI706136B (fr)
UA (1) UA122564C2 (fr)
UY (1) UY36325A (fr)
WO (1) WO2016048833A2 (fr)
ZA (1) ZA201702899B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501413A (zh) 2012-09-27 2017-12-22 中外制药株式会社 Fgfr3融合基因和以其作为标靶的药物
JP6731254B2 (ja) * 2014-01-24 2020-07-29 公益財団法人がん研究会 新規融合体及びその検出法
WO2015144804A1 (fr) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinaisons
PT3198033T (pt) 2014-09-26 2022-05-25 Janssen Pharmaceutica Nv Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr
TWI834020B (zh) 2015-02-10 2024-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP7085985B2 (ja) * 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
EP3628071B1 (fr) 2018-07-27 2022-07-06 Zepto Life Technology, LLC Système et procédé de préparation d'échantillon dans la détection gmr de biomarqueurs
EA202190826A1 (ru) * 2018-09-21 2021-06-16 Янссен Фармацевтика Нв Лечение холангиокарциномы
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
PH12021552352A1 (en) 2019-03-29 2022-09-05 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CA3130460A1 (fr) * 2019-03-29 2020-10-08 Anne Elizabeth O'HAGAN Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothelial
PH12021552973A1 (en) * 2019-05-31 2022-07-11 Qed Therapeutics Inc Methods of treating urinary system cancers
CN110241183B (zh) * 2019-06-13 2022-10-28 南京世和基因生物技术股份有限公司 一种fgfr融合基因的检测方法、试剂盒以及探针库
JPWO2021010326A1 (fr) * 2019-07-12 2021-01-21
CN115335701A (zh) * 2019-09-09 2022-11-11 泽普托生命技术有限责任公司 用于检测核酸中基因变异的系统和方法
KR20220070243A (ko) 2019-09-26 2022-05-30 얀센 파마슈티카 엔.브이. 순차적 치료 환경에서 면역 체크포인트 억제제에 대한 환자 반응을 향상시키기 위한 fgfr-유전적으로 변경된 암에서의 fgfr 억제제의 용도
KR20220140781A (ko) 2020-02-12 2022-10-18 얀센 파마슈티카 엔.브이. 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
BR112022020846A2 (pt) * 2020-04-15 2022-12-27 Alkermes Pharma Ireland Ltd Agentes imunoestimuladores em combinação com inibidores de angiogênese
CN111440790A (zh) * 2020-05-08 2020-07-24 公安部物证鉴定中心 唾液斑迹dna和rna同时提取的方法
JP2023542296A (ja) 2020-09-14 2023-10-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｆｇｆｒ阻害剤の併用療法
CN112143815B (zh) * 2020-11-25 2021-02-26 江苏申基生物科技有限公司 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法
AU2022277796A1 (en) 2021-05-19 2024-01-18 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
EP4415692A1 (fr) 2021-10-12 2024-08-21 TARIS Biomedical LLC Formulations d'erdafitinib et systèmes d'administration intravésicale
KR20240145513A (ko) 2022-02-18 2024-10-07 타리스 바이오메디컬 엘엘씨 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템
AU2024222187A1 (en) 2023-02-13 2025-10-02 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
IL322667A (en) 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
EP4665343A1 (fr) 2023-02-17 2025-12-24 TARIS Biomedical LLC Erdafitinib pour administration intravésicale destiné à être utilisé dans le traitement du cancer de la vessie
WO2025059602A1 (fr) 2023-09-14 2025-03-20 Taris Biomedical Llc Méthodes de traitement du cancer de la vessie à l'aide d'une administration intravésicale d'erdafitinib
CN119219611B (zh) * 2024-12-03 2025-04-18 南京诺源医疗器械有限公司 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
CA2372990C (fr) 1999-05-05 2007-06-19 Institut Curie Moyens de detection et de traitement des pathologies associees au fgfr3
ES2447566T3 (es) 2002-10-01 2014-03-12 Epigenomics Ag Uso de ácidos nucleicos de PITX2 para mejorar el tratamiento de trastornos proliferativos de células mamarias
WO2004085676A1 (fr) * 2003-03-26 2004-10-07 Progenika Biopharma, S.A. Methode de detection in vitro du carcinome a cellules transitionnelles de la vessie
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1659175A1 (fr) * 2004-11-18 2006-05-24 Institut Curie Altérations des kératoses séborrhéiques et applications dérivées
EP2266974A1 (fr) 2005-05-23 2010-12-29 Novartis AG Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
WO2007061127A1 (fr) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. Agent antitumeur pour myelomes multiples
JP2009523410A (ja) 2005-12-08 2009-06-25 ノバルティス アクチエンゲゼルシャフト 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
EP1918376A1 (fr) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques
US20100075337A1 (en) 2007-02-27 2010-03-25 Diana Graus Porta Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereof
WO2008109369A2 (fr) 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
WO2008157801A2 (fr) 2007-06-21 2008-12-24 Gen-Probe Incorporated Instruments et réceptacles pour effectuer des procédés
US8071338B2 (en) 2007-08-08 2011-12-06 Roche Molecular Systems, Inc. Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity
WO2013173485A1 (fr) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Détection de cancers de la vessie
WO2013173480A1 (fr) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Détection de récurrence de cancer de la vessie
GB0718542D0 (en) 2007-09-22 2007-10-31 Univ Dundee Targeted modulation of gene expression
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
CN102448984A (zh) 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
WO2011027219A1 (fr) 2009-09-04 2011-03-10 Progenika Biopharma, S.A. Détection à rendement élevé de petites délétions et insertions génomiques
WO2011115937A1 (fr) * 2010-03-14 2011-09-22 The Translational Genomics Research Institute Procédés de détermination de la sensibilité de tumeurs à des inhibiteurs de la tyrosine kinase
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102293770A (zh) * 2011-05-25 2011-12-28 温州医学院 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂
CN102319224B (zh) * 2011-07-27 2013-03-20 赛乐医药科技(上海)有限公司 复方甲氧那明的速释－缓释渗透泵制剂
WO2013026027A1 (fr) 2011-08-18 2013-02-21 Nestec S.A. Compositions et procédés pour la détection de variants alléliques
EP2761300A4 (fr) * 2011-09-27 2015-12-02 Univ Michigan Fusions de gènes récurrentes dans le cancer du sein
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (fr) * 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3
PT2824181T (pt) 2012-03-08 2018-12-20 Astellas Pharma Inc Novo produto de fusão de fgfr3
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209609D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN104619840A (zh) * 2012-07-05 2015-05-13 日本国立癌症研究中心 Fgfr2融合基因
CN104797936B (zh) * 2012-07-24 2017-11-24 纽约市哥伦比亚大学理事会 融合蛋白及其方法
RU2015102194A (ru) * 2012-07-27 2016-09-20 Дженентек, Инк. Способы лечения связанных с fgfr3 состояний
CN107501413A (zh) 2012-09-27 2017-12-22 中外制药株式会社 Fgfr3融合基因和以其作为标靶的药物
ES2949394T3 (es) * 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
CA3150658A1 (en) * 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP2981621B1 (fr) 2013-04-05 2019-05-22 Life Technologies Corporation Fusions géniques
WO2014193229A2 (fr) 2013-05-27 2014-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Nouvelles translocations dans le cancer du poumon
WO2015006723A1 (fr) 2013-07-12 2015-01-15 The Regents Of The University Of Michigan Fusions de gènes récurrentes dans le cancer
PT3198033T (pt) 2014-09-26 2022-05-25 Janssen Pharmaceutica Nv Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr
US20200208224A1 (en) 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
BR112019016043A2 (pt) 2017-02-06 2020-03-31 Janssen Pharmaceutica Nv Tratamento de câncer

Also Published As

Publication number Publication date
MY194567A (en) 2022-12-02
US20190078166A1 (en) 2019-03-14
JO3681B1 (ar) 2020-08-27
CA2962075C (fr) 2025-09-09
WO2016048833A3 (fr) 2016-05-19
KR102470456B1 (ko) 2022-11-23
DK3198033T3 (da) 2022-04-11
JP7051920B2 (ja) 2022-04-11
IL291633A (en) 2022-05-01
AU2025201448A1 (en) 2025-03-20
KR102839867B1 (ko) 2025-07-28
SG11201702381QA (en) 2017-04-27
EA037920B1 (ru) 2021-06-07
CY1125190T1 (el) 2024-12-13
GT201700059A (es) 2019-08-21
KR20250119657A (ko) 2025-08-07
CO2017003528A2 (es) 2017-07-11
UY36325A (es) 2016-04-01
CN107002141B (zh) 2021-11-02
KR20220162823A (ko) 2022-12-08
CN113957146A (zh) 2022-01-21
AU2015321626B2 (en) 2021-12-16
UA122564C2 (uk) 2020-12-10
JP7558216B2 (ja) 2024-09-30
ECSP17025787A (es) 2018-07-31
CN107002141A (zh) 2017-08-01
JP2024112991A (ja) 2024-08-21
IL251264A0 (en) 2017-05-29
JP2020124192A (ja) 2020-08-20
SI3198033T1 (sl) 2022-06-30
JP2017529090A (ja) 2017-10-05
EP4063516A1 (fr) 2022-09-28
WO2016048833A2 (fr) 2016-03-31
HRP20220496T1 (hr) 2022-05-27
MA40761B1 (fr) 2022-04-29
ZA201702899B (en) 2019-06-26
MX2022006536A (es) 2022-07-11
EP3198033B1 (fr) 2022-02-16
LT3198033T (lt) 2022-05-10
US12037644B2 (en) 2024-07-16
US20160090633A1 (en) 2016-03-31
PT3198033T (pt) 2022-05-25
TW201619609A (zh) 2016-06-01
NZ730886A (en) 2024-08-30
MX2017003954A (es) 2017-12-14
AR102345A1 (es) 2017-02-22
NI201700035A (es) 2017-06-22
IL251264B (en) 2022-04-01
MX392774B (es) 2025-03-24
AU2021277633A1 (en) 2021-12-23
SV2017005415A (es) 2017-07-03
IL291633B1 (en) 2025-12-01
AU2021277633B2 (en) 2024-11-28
HUE058219T2 (hu) 2022-07-28
EA201790716A1 (ru) 2017-10-31
ES2912567T3 (es) 2022-05-26
JP6766037B2 (ja) 2020-10-07
SMT202200177T1 (it) 2022-05-12
JP2022109910A (ja) 2022-07-28
KR20170062495A (ko) 2017-06-07
US20240309463A1 (en) 2024-09-19
PH12017500556A1 (en) 2017-08-30
TWI706136B (zh) 2020-10-01
PL3198033T3 (pl) 2022-08-29
BR112017006088A2 (pt) 2017-12-19
IL324511A (en) 2026-01-01
CR20170104A (es) 2017-05-31
RS63178B1 (sr) 2022-06-30
EP3198033A2 (fr) 2017-08-02
CA2962075A1 (fr) 2016-03-31
AU2015321626A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
MA40761A (fr) Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr
IL260400B (en) Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
IL262805A (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
EP3411505A4 (fr) Détection et diagnostic d'évolution d'un cancer
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
EP2839037A4 (fr) Biomarqueurs permettant d'identifier des patients qui réagiront à un traitement, et traitement desdits patients
EP3465218A4 (fr) Biomarqueurs liés aux maladies hépatiques et leurs méthodes d'utilisation
IL299325A (en) Acid-alpha glucosidase variants and uses thereof
IL254080A0 (en) Methods for the detection and quantification of il-13 and uses in the diagnosis and treatment of diseases related to th2
DK3502667T3 (da) Lysdetekteringsanordninger med beskyttende foring og metoder i forbindelse med samme
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
EP3186397A4 (fr) Utilisation de biomarqueurs de cellules circulant dans le sang pour la détection et le diagnostic de maladies, et leurs procédés d'isolement
EP3387155A4 (fr) Procédés de traitement et de sélection de patients sensibles à l'immunothérapie anticancéreuse
FR3026745B1 (fr) Methode d'analyse et interpretation automatisee d'un antibiogramme
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
EP3678692A4 (fr) Stratification du génotype dans le traitement et la prévention du diabète
EP3258964A4 (fr) Détection et traitement de tumeurs malignes dans le snc
EP3303402A4 (fr) Anticorps contre le glypicane-3 et leurs utilisations dans le diagnostic et le traitement du cancer
GB201716240D0 (en) Relevancy assessment and visualization of biological pathways
EP3419614A4 (fr) Traitement de patients atteints d'hypercholestérolémie familiale homozygote et suivant un traitement hypolipémiant
EP3397063A4 (fr) Utilisation de microbulles et de nanobulles dans le traitement de liquide
FR3007287B1 (fr) Composition comprenant l'association d'un polymere acrylique et d'une silicone aminee
PL3274710T3 (pl) Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów
EP3374370A4 (fr) Procédés de détection et de traitement de l'hypertension pulmonaire
EP3430406A4 (fr) Méthode de diagnostic et de pronostic d'un cancer